{"id":"NCT00608023","sponsor":"Theratechnologies","briefTitle":"TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy","officialTitle":"A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a GHRH Analog, in HIV Subjects With Excess Abdominal Fat Accumulation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2008-02-06","resultsPosted":"2014-01-15","lastUpdate":"2022-09-30"},"enrollment":263,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lipodystrophy","HIV Infections"],"interventions":[{"type":"DRUG","name":"Tesamorelin","otherNames":["Egrifta"]},{"type":"DRUG","name":"Placebo for Tesamorelin","otherNames":[]}],"arms":[{"label":"Tesamorelin 12 months (T-T)","type":"EXPERIMENTAL"},{"label":"Tesamorelin-Placebo (T-P)","type":"EXPERIMENTAL"},{"label":"Placebo-Tesamorelin (P-T)","type":"EXPERIMENTAL"}],"summary":"Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation","primaryOutcome":{"measure":"Changes From Baseline in Fasting Blood Glucose at Week 52","timeFrame":"Baseline and Week 52","effectByArm":[{"arm":"Tesamorelin 52 Weeks","deltaMin":0,"sd":16},{"arm":"Tesamorelin (26 Weeks) - Placebo (26 Weeks)","deltaMin":-2,"sd":34},{"arm":"Placebo (26 Weeks) - Tesamorelin (26 Weeks)","deltaMin":1,"sd":21}],"pValues":[{"comp":"OG000 vs OG001","p":">0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":47,"countries":["United States","Belgium","Canada","France","Spain","United Kingdom"]},"refs":{"pmids":["28832410","22495074","20554713","20101189"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":92},"commonTop":["Upper respiratory tract infection","Diarrhoea","Paresthesia","Injection site erythema","Musculosketal stiffness"]}}